AERIのチャート
AERIの企業情報
| symbol | AERI |
|---|---|
| 会社名 | Aerie Pharmaceuticals Inc （アエリ―・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アエリー･ファーマシューティカル(Aerie Pharmaceuticals Inc.)は臨床病期の製薬会社である。同社は緑内障及び眼の他の疾患の患者のための治療法の発見・開発・商業化に従事する。同社の製品候補には、Rhopressa（netarsudil点眼液）0.02％（Rhopressa）、Roclatan（netarsudil /ラタノプロスト点眼液）0.02％/ 0.005％（Roclatan）が含まれる。同社の製品候補は、開放隅角緑内障および高眼圧症患者の眼内圧（IOP）を下げるように設計される。そのRhopressaは1日1回の点眼薬である。Rhopressaは、IOPを低下させる生化学的標的であるRhoキナーゼ（ROCK）およびノルエピネフリントランスポーター（NET）を阻害する。そのRoclatanは、オープンアングルの緑内障患者の治療薬として処方されているRhopressaとlatanoprostの1日1回、固定用量の組み合わせである。同社はRoclatanの第III相臨床試験を実施している。 アエリ―・ファ―マシュ―ティカルズは米国の製薬会社。緑内障とその他目の疾患治療薬の発見、開発、商業化を行う。緑内障と高眼圧症向けに一日一回投薬で眼圧を下げるRhoキナ―ゼ阻害剤「ロ―プレッサ」と「ロクラタン」の第3相治験を行う。また、第2世代のRhoキナ―ゼ阻害剤が臨床前段階。本社はカリフォルニア州。 |
| 本社所在地 | 4301 Emperor Boulevard Suite 400 Durham CA 27703 USA |
| 代表者氏名 | Vicente Anido ヴィセンテ・アニード |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 919-313-9650 |
| 設立年月日 | 38504 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 160人 |
| url | www.aeriepharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aeri |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -187.08400 |
| 終値（lastsale） | 54.17 |
| 時価総額（marketcap） | 2449689445.01 |
| 時価総額 | 時価総額（百万ドル） 2406.276 |
| 売上高 | 売上高（百万ドル） 2.42300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2244.172 |
| 当期純利益 | 当期純利益（百万ドル） -186.60800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aerie Pharmaceuticals Inc revenues increased from $0K to $2.4M. Net loss increased 77% to $95.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative -Other increase from $22.6M to $53.3M (expense) Research and development - Other increase of 39% to $26.5M (expense). |
AERIのテクニカル分析
AERIのニュース
Rho Associated Protein Kinase 2 Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast 2027| Aerie Pharmaceuticals, DWTI, 2021/01/12 14:14:09 OpenPR
Los Angeles United States: The global Rho Associated Protein Kinase 2 market is researched with great precision and in a comprehensive manner to help you identify hidden opportunities and become informed about unpredictable challenges in the industry. The authors of the
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% 2021/01/11 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Commission (EC) has granted a marketing authorisation for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intraocu
Global Glaucoma Disease Insights and Market Forecasts to 2026 Featuring Novartis, Allergan, Pfizer, Santen Pharmaceutical, Akorn, Aerie Pharmaceuticals, & AbbVie - ResearchAndMarkets.com 2020/12/14 13:03:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Glaucoma - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering. "Glaucoma: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Glaucoma disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Glaucoma, drug wise in $ sales and patient numbers at globa
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union 2020/11/13 11:50:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation appli
Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference 2020/11/10 12:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17,
Global Glaucoma Disease Insights and Market Forecasts to 2026 Featuring Novartis, Allergan, Pfizer, Santen Pharmaceutical, Akorn, Aerie Pharmaceuticals, & AbbVie - ResearchAndMarkets.com 2020/12/14 13:03:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Glaucoma - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering. "Glaucoma: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Glaucoma disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Glaucoma, drug wise in $ sales and patient numbers at globa
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union 2020/11/13 11:50:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation appli
Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference 2020/11/10 12:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17,
Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update 2020/11/05 21:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a general business update. “Our third quarter results demonstrated over 12 percent sequential growth in o
Ophthalmic Drugs Market With Top Players like Aerie Pharmaceuticals, Allergan, Bausch Health Companies, Santen Pharmaceutical Co., Ltd. Regeneron, Novartis AG, Bayer AG, Otsuka Pharmaceutical Co., Ltd. F. Hoffmann-La Roche Ltd, Pfizer 2020/11/04 08:02:57 OpenPR
Ophthalmic drugs are sterile preparations designed to treat several eye disorders. These are used in the treatment of dry eye, age-related macular degeneration, diabetic retinopathy, and other eye disorders. An off-the-shelf report on Ophthalmic Drugs Market which has been compiled after
Global Glaucoma Disease Insights and Market Forecasts to 2026 Featuring Novartis, Allergan, Pfizer, Santen Pharmaceutical, Akorn, Aerie Pharmaceuticals, & AbbVie - ResearchAndMarkets.com 2020/12/14 13:03:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Glaucoma - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering. "Glaucoma: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Glaucoma disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Glaucoma, drug wise in $ sales and patient numbers at globa
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union 2020/11/13 11:50:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation appli
Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference 2020/11/10 12:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17,
Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update 2020/11/05 21:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a general business update. “Our third quarter results demonstrated over 12 percent sequential growth in o
Ophthalmic Drugs Market With Top Players like Aerie Pharmaceuticals, Allergan, Bausch Health Companies, Santen Pharmaceutical Co., Ltd. Regeneron, Novartis AG, Bayer AG, Otsuka Pharmaceutical Co., Ltd. F. Hoffmann-La Roche Ltd, Pfizer 2020/11/04 08:02:57 OpenPR
Ophthalmic drugs are sterile preparations designed to treat several eye disorders. These are used in the treatment of dry eye, age-related macular degeneration, diabetic retinopathy, and other eye disorders. An off-the-shelf report on Ophthalmic Drugs Market which has been compiled after